Alembic Pharmaceuticals Limited, released its unaudited financial results for the second quarter and half-year ended on September 30, 2023. Here is a detailed summary of the provided information:
- Financial Results:
- Net Sales for the quarter increased by 8% to Rs. 1595 crores.
- Net Profit for the quarter amounted to Rs. 137 crores.
- Net Sales for the first half of the fiscal year grew by 13% to Rs. 3081 crores.
- Net Profit for the first half of the fiscal year was Rs. 257 crores.
- Operational Highlights:
- Despite challenges in the antibiotic and respiratory market, Alembic Pharmaceuticals reported a satisfactory quarter, with strong performance in its specialty and animal healthcare portfolio.
- The India Branded Business witnessed 5% growth in Q2FY24, with specialty therapies growing by 10%.
- The company outperformed the market in antibiotic and respiratory segments.
- The Animal Health business recorded significant growth of 32% over the previous year’s Q2.
- The US Generics segment saw a 6% YoY growth and a 14% QoQ growth.
- Ex-US International Formulations experienced a 17% growth during the quarter.
- The company received 6 ANDA approvals and filed 2 ANDAs during the quarter.
- The API Business grew by 10% in the quarter, with 132 cumulative DMF filings.
- Total Revenue:
- The total revenue for the quarter was Rs. 1595 crores, an 8% increase compared to the previous year’s Q2.
- The total revenue for the first half of the fiscal year was Rs. 3081 crores, marking a 13% growth.
Subscribe To Our Free Newsletter |